Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from BridgeBio Pharma

This Hot Biotech Stock Just Set New All-Time Highs

BridgeBio Pharma (BBIO) has surged 145% over the past year, reaching an all-time high of $75.10. BBIO maintains a strong technical profile with a 100% “Buy” Barchart opinion. Revenue is projected to grow 123% this year and 79.63% next year, though earnings will dip 61.11% before rebounding 44.41%. Despite bullish...

Barchart

Should You Grab This ‘Strong Buy’ Growth Stock With 56% Upside?

With one blockbuster product, this biotech is gearing up for more product launches next year.

Barchart

BridgeBio's Acoramidis Cuts Risk Within Weeks In Rare Heart Condition

BridgeBio Pharma, Inc. (NASDAQ: BBIO) on Sunday presented data from the ATTRibute-CM study.

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

Is This Biotech Stock With 150% Upside a Buy Now?

The high price estimate for BridgeBio Pharma suggests potential upside of 150% in 2025.

Barchart

BridgeBio Pharma, Rigetti Computing, Bath & Body Works And Other Big Stocks Moving Higher On Monday

U.S. stocks were higher, with the Dow Jones index gaining more than 400 points on Monday.

Benzinga

Recap Of Thursday's Biotech Catalysts - End Of the Day Summary

The US Food and Drug Administration (FDA) has accepted for filing Krystal Biotech’s (NASDAQ:KRYS) Biologics License Application (BLA) for its lead candidate B-VEC in the treatment of patients with dystrophic epidermolysis bullosa (DEB). The regulatory agency has granted Priority Review designation and assigned a target actin date of February 17,…

Benzinga

Recap Of Wednesday's Biotech Catalysts - End Of the Day Summary

Bristol Myers Squibb (NYSE:BMY) and 2seventy bio (NASDAQ:TSVT) announced positive topline results from KarMMa-3, a Phase 3 study evaluating Abecma (idecabtagene vicleucel) compared to standard combination regimens in adults with multiple myeloma that is relapsed and refractory. Bristol Myers shares traded in a range of $73.95 to $75.32 on a day volume…

Benzinga

Read news from The Economist, FT, and more,
with one subscription

12 Health Care Stocks Moving In Wednesday's Intraday Session

Benzinga

Recap Of Tuesday's Biotech Catalysts - End of The Day Summary

European Commission (EC) has approved AbbVie’s (NYSE:ABBV) lead asset RINVOQ (upadacitinib 45 mg [induction dose] and 15 mg and 30 mg [maintenance doses]) for the treatment of adult patients with moderately to severely active ulcerative colitis. AbbVie shares traded in a range of $150.33 to $153.56 on a day volume…

Benzinga

BridgeBio Pharma Posts Promising Data From Gene Therapy Trial In Ultra-Rare Disease

BridgeBio Pharma Inc (NASDAQ:BBIO) announced promising pharmacodynamic data from the first two participants dosed in CANaspire Phase 1/2 trial of BBP-812, gene therapy for Canavan disease. Canavan disease is an ultra-rare inherited disorder that damages the ability of nerve cells (neurons) in the brain to send and receive messages. Data from the first…

Benzinga

BridgeBio Pharma Reveals Early Positive Data For Canavan Disease

BridgeBio Pharma (NASDAQ: BBIO) announced early positive data from the the first two participants dosed in CANaspire clinical study for the treatment of Canavan disease.

Benzinga

BridgeBio Pharma's Return On Capital Employed Insights

Benzinga Pro data, BridgeBio Pharma (NASDAQ:BBIO) reported Q1 sales of $1.69 million. Earnings fell to a loss of $201.33 million, resulting in a 32.21% decrease from last quarter.

Benzinga

6 Analysts Have This to Say About BridgeBio Pharma

Over the past 3 months, 6 analysts have published their opinion on BridgeBio Pharma (NASDAQ:BBIO) stock. These analysts are typically employed by large Wall Street banks and tasked with understanding a company's business to predict how a stock will trade over the upcoming year.

Benzinga

Where BridgeBio Pharma Stands With Analysts

BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter:

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Recap: BridgeBio Pharma Q1 Earnings

BridgeBio Pharma (NASDAQ:BBIO) reported its Q1 earnings results on Thursday, May 5, 2022 at 07:00 AM. Here's what investors need to know about the announcement. Earnings BridgeBio Pharma reported an EPS of $1.35.

Benzinga

BridgeBio Pharma Highlights Mid-Stage Study Data Of Acoramidis In Cardiomyopathy Trial

BridgeBio Pharma Inc (NASDAQ: BBIO)

Benzinga

What 6 Analyst Ratings Have To Say About BridgeBio Pharma

BridgeBio Pharma (NASDAQ:BBIO) has observed the following analyst ratings within the last quarter:

Benzinga

Where BridgeBio Pharma Stands With Analysts

Analysts have provided the following ratings for BridgeBio Pharma (NASDAQ:BBIO) within the last quarter:

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

BridgeBio Pharma Posts Updated Data From Muscular Dystrophy Trial, Plots Path To Market

BridgeBio Pharma Inc (NASDAQ: BBIO) has

Benzinga

Sentynl Buys BridgeBio Pharma's Fosdenopterin Rights In Genetic Disorder

BridgeBio Pharma Inc (NASDAQ: BBIO)

Benzinga

Helsinn, BridgeBio Pharma Amend Infigratinib Pact For Oncology Indications

Helsinn Group and BridgeBio Pharma Inc (NASDAQ: BBIO) have

Organisations

Food and Drug Administration

European Medicines Agency

Alnylam Pharmaceuticals

29 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Topics

Amyotrophic lateral sclerosis

29 stories

Read news from The Economist, FT, and more,
with one subscription

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.